Germany to ban therapeutic cloning "for now":
This article was originally published in Clinica
Germany's national ethics council this week decide that cloning for research purposes must be put on hold for the present. However, 12 of the council's 25 members still believe that therapeutic cloning could be ethically defended and so the agreement represents a compromise after a year-long debate on the subject. Although only five members wanted a blanket ban on all forms of cloning, the compromise still represents a blow to tissue engineering companies in Germany, who were aiming to press ahead with harvesting stem cells from therapeutic clones. Research minister Edelgard Buhlman welcomed the council's ruling and said: "At this point we do not see any reason to alter the existing ban contained in the embryo protection law."
You may also be interested in...
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.